Aurobindo to acquire Spectrum’s oncology injectables portfolio
Aurobindo Pharma is making a play to get into branded oncology products.
Aurobindo subsidiary Acrotech Biopharma is acquiring a portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals. The company said the acquisition is intended to help Aurobindo Group enter the branded oncology market with a range of products known to the oncology community.
Aurobindo Group also said it will acquire branded commercial infrastructure to continue commercializing these brands.
“We are excited to jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated medications and leveraging strategic partnerships,” Acrotech president Ashish Anvekar said. “We look forward to welcome an experienced team of employees from Spectrum who are essential to our mission.”
Aurobindo managing director N. Govindarajan said, “The acquisition announced today creates an ideal launch pad for Acrotech, and establishes our presence in the branded market, which is in line with our strategy to grow and diversify our business in the United States.”
The transaction is expected to close within 90 days.
Aurobindo subsidiary Acrotech Biopharma is acquiring a portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals. The company said the acquisition is intended to help Aurobindo Group enter the branded oncology market with a range of products known to the oncology community.
Aurobindo Group also said it will acquire branded commercial infrastructure to continue commercializing these brands.
“We are excited to jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated medications and leveraging strategic partnerships,” Acrotech president Ashish Anvekar said. “We look forward to welcome an experienced team of employees from Spectrum who are essential to our mission.”
Aurobindo managing director N. Govindarajan said, “The acquisition announced today creates an ideal launch pad for Acrotech, and establishes our presence in the branded market, which is in line with our strategy to grow and diversify our business in the United States.”
The transaction is expected to close within 90 days.